-- The Trendlines (SGX:42T) subsidiary, Vensica Medical, received approval from the U.S. Food and Drug Administration (FDA) to initiate Phase 2 clinical trials for its VixE drug delivery system, according to a Monday filing with the Singapore Exchange.
Shares of the medical and other services company were up nearly 5% in Tuesday trading.
The needle-free delivery system is being developed for the treatment of overactive bladder, with the phase 2 study expected to conduct trials across around 210 patients in the U.S. and Europe.